Skip to main content
SpringerLink
Log in

The Role of Surgery and Tyrosine Kinase Inhibitors in the Management of Advanced or Recurrent GIST

  • Chapter
  • First Online:
Unusual Cases in Peritoneal Surface Malignancies

  • 417 Accesses

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal sarcoma, accounting for 5% of all mesenchymal tumors and 1–3% of all gastrointestinal tumors. The annual incidence is 10–13 per 1,000,000, with the majority arising in the stomach (50–60%) and small bowel (20–30%) and only a minority in the large bowel (5%) and esophagus (<5%) [1, 2]. GISTs arise from activating mutations of tyrosine kinase receptors, most commonly by KIT (CD117) which is expressed in 95% of GISTs or platelet-derived growth factor receptor (PDGFR) which is mutated in 5–10% of GISTs. Yet, 10–15% have no known mutation in KIT or PDGRF and are wild type. The treatment of GISTs has dramatically changed since 2002 due to the FDA approval of imatinib/Gleevec, a tyrosine kinase inhibitor (TKI) of c-KIT. Imatinib has initial response rates of 75–80% [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Quek R, George S. Gastrointestinal stromal tumor: a clinical overview. Hematol Oncol Clin N Am. 2009;23:69–78. viii

    Article  Google Scholar 

  2. Maki RG, Blay JY, Demetri GD, et al. Key issues in the clinical management of gastrointestinal stromal tumors: an expert discussion. Oncologist. 2015;20:823–30.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg. 2003;186:665–9.

    Article  PubMed  Google Scholar 

  4. Gronchi A, Raut CP. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. Ann Surg Oncol. 2012;19:1051–5.

    Article  PubMed  Google Scholar 

  5. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004;64:5913–9.

    Article  CAS  PubMed  Google Scholar 

  6. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:4182–90.

    Article  CAS  Google Scholar 

  7. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–9.

    Article  CAS  PubMed  Google Scholar 

  8. McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009;16:910–9.

    Article  PubMed  Google Scholar 

  9. von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2016;14:758–86.

    Google Scholar 

  10. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14–24.

    Article  PubMed  Google Scholar 

  11. de la Fuente SG, Deneve JL, Parsons CM, Zager JS, Conley AP, Gonzalez RJ. A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. HPB: Off J Int Hepatol Pancreatol Biliary Assoc. 2013;15:655–60.

    Article  Google Scholar 

  12. Turley RS, Peng PD, Reddy SK, et al. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer. 2012;118:3571–8.

    Article  PubMed  Google Scholar 

  13. Zaydfudim V, Okuno SH, Que FG, Nagorney DM, Donohue JH. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors. J Surg Res. 2012;177:248–54.

    Article  PubMed  Google Scholar 

  14. Haller F, Detken S, Schulten HJ, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007;14:526–32.

    Article  PubMed  Google Scholar 

  15. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007;245:347–52.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18:2676–84.

    Article  CAS  PubMed  Google Scholar 

  17. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000;36:61–7.

    Article  CAS  PubMed  Google Scholar 

  18. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19:3483–9.

    Article  CAS  PubMed  Google Scholar 

  19. Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608–15.

    Article  PubMed  Google Scholar 

  20. Gold JS, van der Zwan SM, Gonen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol. 2007;14:134–42.

    Article  PubMed  Google Scholar 

  21. DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258:422–9.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–72.

    Article  CAS  PubMed  Google Scholar 

  24. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bauer S, Rutkowski P, Hohenberger P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40:412–9.

    CAS  Google Scholar 

  26. Bischof DA, Kim Y, Blazer 3rd DG, et al. Surgical management of advanced gastrointestinal stromal tumors: an international multi-institutional analysis of 158 patients. J Am Coll Surg. 2014;219:439–49.

    Article  PubMed  Google Scholar 

  27. Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007;245:341–6.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325–31.

    Article  CAS  PubMed  Google Scholar 

  29. Levine EA, Stewart JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204:943–53. discussion 53–5

    Article  PubMed  Google Scholar 

  30. Randle RW, Swett KR, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis. Am Surg. 2013;79:620–4.

    PubMed  PubMed Central  Google Scholar 

  31. Rossi CR, Deraco M, De Simone M, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer. 2004;100:1943–50.

    Article  PubMed  Google Scholar 

  32. Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218:573–85.

    Article  PubMed  Google Scholar 

  33. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey F, Eilber FR. Recurrent gastrointestinal stromal sarcomas. Surg Oncol. 2000;9:71–5.

    Article  CAS  PubMed  Google Scholar 

  34. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol. 1999;6:645–50.

    Article  CAS  PubMed  Google Scholar 

  35. Bryan ML, Fitzgerald NC, Levine EA, Shen P, Stewart JH, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in sarcomatosis from gastrointestinal stromal tumor. Am Surg. 2014;80:890–5.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Oncology, Wake Forest Baptist Health, Winston-Salem, NC, USA

    Rebecca M. Dodson MD, Perry Shen MD, Edward A. Levine MD & Konstantinos I. Votanopoulos MD, PhD

  2. Surgical Oncology, Wake Forest University, Medical Center Blvd, Winston-Salem, North Carolina, 27157, USA

    Konstantinos I. Votanopoulos MD, PhD

Authors
  1. Rebecca M. Dodson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Perry Shen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward A. Levine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Konstantinos I. Votanopoulos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantinos I. Votanopoulos MD, PhD .

Editor information

Editors and Affiliations

  1. Peritoneal Dissemination Treatment, Istanbul, Turkey

    Emel Canbay

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Dodson, R.M., Shen, P., Levine, E.A., Votanopoulos, K.I. (2017). The Role of Surgery and Tyrosine Kinase Inhibitors in the Management of Advanced or Recurrent GIST. In: Canbay, E. (eds) Unusual Cases in Peritoneal Surface Malignancies . Springer, Cham. https://doi.org/10.1007/978-3-319-51523-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-51523-6_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-51522-9

  • Online ISBN: 978-3-319-51523-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation